A long-acting insulin analogue for use in reducing the risk of hypoglycemia in a patient suffering from diabetes and requiring amounts of insulin supplied of more than 80 U / administration, where the long-acting insulin analog is administered once a day as a single injection to said patient in an amount of more than 80 U / administration and in the form of a pharmaceutical composition comprising said insulin at a concentration of 200 U / ml or more, and wherein the insulin analogue Long-acting insulin is a naturally occurring insulin or an insulin analogue that has a side chain attached to either the -amino group of the N-terminal amino acid residue of the B chain or the -amino group of a Lys residue present in the parental insulin B chain, the side chain is of the general formula (I): -WXYZ where W is: - an amino acid residue having a carboxylic acid group in the side chain cu The residue forms, with one of its carboxylic acid groups, an amide group together with the -amino group of the N-terminal amino acid residue of the B chain or together with the -amino group of a Lys residue present in the parental insulin B chain； - a chain composed of two, three or four residues of - amino acids linked together by means of amide bonds, whose chain - by means of an amide bond - is linked to the --amino group of the N-terminal amino acid residue of chain B or to the --amino group of a Lys residue present in the parental insulin B chain, the amino acid residues of W are selected from the group of amino acid residues that have a neutral side chain and amino acid residues that have a carboxylic acid group in the side chain so that W has at least one amino acid residue having a carboxylic acid group in the side chain； or - a covalent bond of X to the - amino group of the N-terminal amino acid residue of the B chain or to the - amino group of a Lys residue present in the B chain of the parental insulin； where X is: - -CO-； - -COCH (COOH) CO-； - -CON (CH2COOH) CH2CO-； - -CON (CH2C
